GREEN - ALPHA 3 MIU/ML (2ML) INJ

INDICATION FOR THE TREATMENT OF CHRONIC HEPATITIS C HAIRY CELL LEUKEMIA AIDS-RELATED KAPOSI S SARCOMA AND CHRONIC MYELOGENOUS LEUKEMIA. ALSO FOR THE TREATMENT OF ORAL WARTS ARISING FROM HIV INFECTION. MECHANISM OF ACTION INTERFERON ALPHA BINDS TO TYPE I INTERFERON RECEPTORS (IFNAR1 AND IFNAR2C) WHICH UPON DIMERIZATION ACTIVATE TWO JAK (JANUS KINASE) TYROSINE KINASES (JAK1 AND TYK2). THESE TRANSPHOSPHORYLATE THEMSELVES AND PHOSPHORYLATE THE RECEPTORS. THE PHOSPHORYLATED INFAR RECEPTORS THEN BIND TO STAT1 AND STAT2 (SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTION)WHICH DIMERIZE AND ACTIVATE MULTIPLE (~100) IMMUNOMODULATORY AND ANTIVIRAL PROTEINS. INTERFERON ALPHA BINDS LESS STABLY TO TYPE I INTERFERON RECEPTORS THAN INTERFERON BETA.